This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Alexion Pharmaceuticals, Inc.
Drug Names(s): T-20, T20-206, T20-208
Description: Fuzeon is the first and only fusion inhibitor for the treatment of HIV. Unlike other HIV drugs that work after HIV has entered the human immune cell, Fuzeon works outside the CD4 cell, blocking HIV from entering the cell. For this reason, Fuzeon is effective in treatment-experienced patients who have developed resistance to other anti-HIV drugs, though patients may still develop resistance to Fuzeon.
Revenue splits for this drug are BioMedTracker estimates.
Fuzeon (enfuvirtide) was originally developed by Trimeris.
Roche and Trimeris
Trimeris entered into a worldwide agreement with Roche to develop and market Fuzeon. The agreement with Roche grants them an exclusive, worldwide license for Fuzeon and and certain other peptide compounds in the field of HIV. Roche may terminate its license as a whole or for a particular country or countries in its sole discretion with advance notice. Trimeris will share development expenses and profits for Fuzeon, or a replacement compound, in the United States and Canada equally with Roche. Outside of the United States and Canada, Roche will fund all development costs and pay us royalties on net sales of Fuzeon, or a replacement compound, for a specified term. In addition, the agreement calls for Trimeris to receive up to $68.0 million in upfront and milestone payments. Roche is responsible for the sales, marketing and...See full deal structure in Biomedtracker
Partners: Roche Holding AG Novartis AG
Pink Sheet Fuzeon Clinical Protocols
Pink Sheet Fuzeon FDA Reviewers
Pink Sheet Fuzeon Clinical Development
Additional information available to subscribers only: